TPMT testing in azathioprine: A 'cost-effective use of healthcare resources'?

Personalized Medicine

Volumn 6, Issue 1, 2009, Pages 103-113

  Payne, Katherine ^a   Newman, William G ^a   Gurwitz, David ^b   Ibarreta, Dolores ^c   Phillips, Kathryn A ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b TEL AVIV UNIVERSITY   (Israel)

^c JOINT RESEARCH CENTRE   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Azathioprine; Cost effectiveness analysis; Economic evaluation; Imuran; Leucopenia; Mercaptopurines; Neutropenia; Pharmacogeneticsthiopurine S methyltransferase; Value of information

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ARTICLE; BONE MARROW SUPPRESSION; BULLOUS PEMPHIGOID; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE INCREASE; ENTERITIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MORTALITY; NEUTROPENIA; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SCREENING TEST; SYSTEMATIC REVIEW;

EID: 67651083364     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.6.1.103     Document Type: Article

References (28)

1. Gurwitz D, Motulsky AG: 'Drug reactions, enzymes, and biochemical genetics': 50 years later. Pharmacogenomics 8(11), 1479-1484 (2007).
2. Fargher EA, Tricker K, Newman W et al.: Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase (TPMT) testing prior to azathioprine prescription. J. Clin. Pharm. Ther. 32, 187-195 (2007).
3. Woelderlink, A Ibarreta D, Hopkins M, Rodriguez-Cerezo E: The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J. 6(1), 3-7 (2006)
4. Sanderson J, Ansari A, Marinaki T, Duley J: Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann. Clin. Biochem. 41, 294-302 (2004).
5. Wang L, Weinshilboum R: Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25(11), 1629-1638 (2006).
6. Yates CR, Krynetski EY, Loennechen T et al.: Molecular diagnosis of thiopurine-S- methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126, 608-616 (1997).
7. Winter JW, Gaffney D, Shapiro D et al.: Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol. Ther. 25, 1069-1077 (2007).
8. Compagni A, Bartoli S, Buehrlen B, Fattore G, Ibarreta D, Gutierrez de Mesa E: Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int. J. Tech. Assess. Health Care 24(3), 294-302 (2008).
9. Vegter S, Boersma C, Rozenbaum M et al.: Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes. A systematic review on content and adherence to guidelines. Pharmacoeconomics 26(7), 569-587 (2008).
10. Drummond M, Sculpher M, Torrance GW, O'Brien BJ, Stoddart G: Metbods for the Economic Evaluation of Health Care Programmes (3rd Edition). Oxford University Press, Oxford, UK (2005).
11. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ: A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100(10), 2239-2247 (2005).
12. Marra CA, Esdaile JM, Anis AH: Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J. Rheumatol. 29(12), 2507-2512 (2002).
13. Oh KT, Anis AH, Bae SC: Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology 43(2), 156-163 (2004).
14. Priest VL, Begg EJ, Gardiner SJ et al.: Pharmacoeconomic analyses of azathioprine, methotrexare and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 24(8), 767-781 (2006).
15. van den Akker-van Marle ME, Gurwit z D, Detmar SB et al.: Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7(5), 783-792 (2006).
16. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR: Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 20(6), 593-599 (2004).
17. Sayani FA, Prosser C, Bailey RJ, Jacobs P, Fedorak RN: Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can. J. Gastroenterol. 19(3), 147-151 (2005).
18. Tavadia SMB, Mydlarski PR, Reis MD et al.: Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J. Am. Acad. Dermatol. 42(4), 628-632 (2000).
19. Provenzale D, Onken JE: TPMT genotype screening for patients about to begin azathioprine treatment - a look at costs and potential benefits. Inflamm. Bowel Dis. 11(12), 1119-1120 (2005).
20. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S: Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality of assessment. Pharmacoeconomics 24, 355-371 (2006).
21. Slanar 0, Chalupnhá P, Novotný A, Bortlík M, Krska Z, Lukás M: Fatal myelotoxicity after azathioprine treatment. Nucleosides Nucleotides Nucleic Acids 27(6), 661-665 (2008).
22. Boonsrirat U, Angsuthum S, Vannaprasaht S et al.: Azathioprine-induced fatal myclosuppression in systemic lupris erythematosus patient carrying TPMT*3C polymorphism. Lupus 17, 132-1324 (2008).
23. Payne K, Newman W, Fargher EA, Tricker K, Bruce I, Ollier WFR: TPMT testing in rheumatology: any better than routine monitoring? Rheumatology 46, 727-729 (2007).
24. Sculpher M, Drummond M, Buxton M: The iterative use of economic evaluation as part of the process of health technology assessment. J. Health Serv. Res. Policy 2(1), 26-30 (1997).
25. Ansari A, Arenas M, Greenfield SM et al.: Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol. Ther. 28(8), 973-983 (2008).
26. Claxton K, Schulpher M, McCabe C et al.: Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 14, 339-347 (2005).
27. Claxton K: The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 18, 341-364 (1999).
28. Claxton K, Ades AE, Lu G: Expected value of sample information in medical decision modeling. Med. Decis. Making 24, 207-228 (2004).